ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $637,231 | -91.5% | 13,698 | -92.3% | 0.00% | -93.9% |
| Q4 2020 | $7,464,000 | -30.3% | 177,288 | -24.2% | 0.03% | -21.4% |
| Q3 2020 | $10,704,000 | +25.2% | 233,820 | +37.3% | 0.04% | -2.3% |
| Q2 2020 | $8,551,000 | -15.4% | 170,324 | -13.4% | 0.04% | -34.8% |
| Q1 2020 | $10,111,000 | -45.5% | 196,605 | -34.5% | 0.07% | +8.2% |
| Q4 2019 | $18,540,000 | +4.3% | 300,085 | +1.4% | 0.06% | -7.6% |
| Q3 2019 | $17,781,000 | +100.3% | 295,954 | +181.3% | 0.07% | +106.2% |
| Q2 2019 | $8,878,000 | +30.7% | 105,211 | +48.0% | 0.03% | +23.1% |
| Q1 2019 | $6,792,000 | +198.8% | 71,111 | +121.6% | 0.03% | +160.0% |
| Q4 2018 | $2,273,000 | -61.1% | 32,088 | -53.1% | 0.01% | -52.4% |
| Q3 2018 | $5,847,000 | -60.7% | 68,417 | -46.7% | 0.02% | -65.6% |
| Q2 2018 | $14,872,000 | -33.3% | 128,317 | -53.5% | 0.06% | -40.2% |
| Q1 2018 | $22,310,000 | – | 275,742 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |